Clinical Trial

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-12-31 -> 2029-03-31 2026-06-27
minor Completion pushed: 2028-12-31 -> 2029-03-31 2026-06-27
Trial Details
NCT Number NCT07110233
Lead Sponsor University of California, San Francisco
Conditions Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
Enrollment 64 participants
Start Date 2026-10-01
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26